Abstract
A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have